Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults
A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Healthy Adults
1 other identifier
interventional
317
1 country
4
Brief Summary
A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine (recombinant) in Healthy Adults. Study Objectives: Primary:
- To assess the tolerability and safety of Influenza VLP Vaccine
- To assess the immunogenicity of Influenza VLP Vaccine as measured by hemagglutination inhibition (HAI) antibody titers to each of the three component viral strains Secondary:
- To evaluate the cross-strain immunogenicity of Influenza VLP Vaccine as measured by hemagglutination inhibition (HAI) antibody titers against drifted strains
- To quantify antibody against neuraminidase and hemagglutinin following administration of Influenza VLP Vaccine
- To assess cell-mediated immune (CMI) responses to Influenza VLP Vaccine as quantified by interferon-gamma (IFNg) and Granzyme-B produced by peripheral blood mononuclear cells (PBMCs).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Sep 2008
Shorter than P25 for phase_2
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2008
CompletedFirst Submitted
Initial submission to the registry
September 16, 2008
CompletedFirst Posted
Study publicly available on registry
September 18, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2009
CompletedJuly 18, 2013
July 1, 2013
6 months
September 16, 2008
July 16, 2013
Conditions
Outcome Measures
Primary Outcomes (2)
To assess the tolerability and safety of Influenza VLP Vaccine
6 Months
To assess the immunogenicity of Influenza VLP Vaccine as measured by hemagglutination inhibition (HAI) antibody titers to each of the component viral strains
Day 22
Secondary Outcomes (3)
To evaluate cross-strain immunogenicity as measured by HAI titers against drifted strains
Day 22
To quantify antibody responses against neuraminidase and hemagglutinin
Day 22
To assess cell-mediated immune (CMI) responses to Influenza VLP Vaccine
Day 11
Study Arms (4)
Low dose
EXPERIMENTALMid dose
EXPERIMENTALHigh dose
EXPERIMENTALPlacebo
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Healthy male or female 18 to 49 years of age at the time of the vaccination.
- Informed consent must be obtained from the subject prior to beginning any study specific procedures indicating that they understand the purpose of this study and are willing to adhere to the procedures described in this protocol.
- Available by telephone.
- Free of obvious health problems or chronic illnesses (i.e., recent exacerbation or acute episode of chronic illness in the last 3 months) as established by medical history, review of systems and clinical examination before entering the study. This includes any mental condition that would interfere with subject self-assessment. Subjects with pre-existing stable disease, defined as no significant disease diagnosed in the month prior to study vaccine receipt and disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before receipt of study vaccine are eligible.
- If subject is of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (e.g., intrauterine contraceptive device; oral contraceptives or other equivalent hormonal contraception) for 3 months prior to vaccination. She must also have a negative pregnancy test at study entry and must agree to continue such precautions for three months after vaccination.
You may not qualify if:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the administration of the study vaccine, or planned use during the study period.
- Has received any other licensed vaccines within 4 weeks prior to enrollment in this study or expected receipt of any vaccination before the final immune response blood collection.
- Has received any influenza vaccine within the prior 6 month period.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the administration of the study vaccine. The use of inhaled and nasal steroids will be permitted.
- Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination.
- Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or during the study.
- Acute disease at the time of enrollment. Acute disease is defined as the presence of a moderate or severe illness with or without fever ≥ 100.5º F.
- Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
- Major congenital defects or serious chronic illness.
- History of any neurological disorders or seizures, with the exception of febrile seizures during childhood.
- Pregnant or lactating female.
- Females planning to become pregnant or planning to discontinue contraceptive precautions within 60 days of enrollment in this study.
- Any condition that in the opinion of the investigator would interfere with evaluation of the vaccine or interpretation of study results.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Novavaxlead
Study Sites (4)
University Clinical Research
Pembroke Pines, Florida, 33024, United States
The Center for Pharmacuetical Research
Kansas City, Missouri, 64114, United States
Omega Medical Research
Warwick, Rhode Island, 02886, United States
Benchmark Research
Austin, Texas, 78705, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
John E Ervin, M.D.
The Center for Pharmaceutical Research
- PRINCIPAL INVESTIGATOR
Laurence Chu, M.D.
Benchmark Research
- PRINCIPAL INVESTIGATOR
Larry Gilderman, D.O.
University Clinical Research
- PRINCIPAL INVESTIGATOR
David L Freid, M.D.
Omega Medical Research
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 16, 2008
First Posted
September 18, 2008
Study Start
September 1, 2008
Primary Completion
March 1, 2009
Study Completion
March 1, 2009
Last Updated
July 18, 2013
Record last verified: 2013-07